Navigation Links
Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated
Date:2/5/2008

rom the study and reported adverse events were generally mild and transient.

"This study is an important step forward in the clinical development of tezampanel. Our ability to safely deliver multiple doses of tezampanel means that we can now pursue virtually any indication that requires chronic dosing," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics. "There is an emerging appreciation of the pathological effects of increased AMPA and kainate receptor activation by glutamate. By blocking both receptors, tezampanel and its oral prodrug, NGX426, may represent a unique and effective approach to treat a variety of chronic pain as well as non-pain conditions."

Tezampanel is the first AMPA/kainate antagonist to be studied in clinical trials for chronic pain. Both tezampanel and NGX426 represent a novel, non-opiod, non-vascular and non-serotonergic approach to treating multiple chronic pain conditions. Tezampanel and NGX426 are antagonists of a subgroup of glutamate receptors referred to as AMPA and kainate. These receptors are found in areas of the central and peripheral nervous system that are important for the transmission of pain. For example, during a migraine attack, levels of glutamate increase and activate these receptors, facilitating the transmission of pain impulses. Tezampanel, by blocking the binding of glutamate to these receptors, is believed to inhibit the transmission of pain signals that lead to migraine headaches. The blockade of similar receptors in other regions of the brain or spinal cord has been shown in animal models to attenuate pathophysiological processes such as the muscle spasticity and rigidity that occurs following stroke and spinal cord injury, or that may be associated with multiple sclerosis.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of small mo
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
2. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
3. Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)
4. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
5. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
6. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
7. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
8. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
9. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
10. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
11. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... - The Taskforce representing Canada,s living ... work that the Minister and Health Canada have put into ... the needs of the thalidomide survivors, and more than 70% ... free, with annual adjustments for inflation. Certain of ... $100,000 based on the severity of their disability, tax free, ...
(Date:5/22/2015)... , 22 de mayo de 2015 ... DPRX ), una compañía farmacéutica de fase ... de Locilex® (pexiganan cream 0.8%), y colaboradores ... presentación de póster destacando el diseño innovador ... de la Compañía que evalúan Locilex®, su ...
(Date:5/22/2015)... HILL, N.C. , May 22, 2015 /PRNewswire/ ... critical to pharmaceutical brand recognition and success. ... LLC conducted a study to provide pharmaceutical and ... of investment (FTEs and budget) that are being ... Pharmaceutical and biotech marketing managers can utilize this ...
Breaking Medicine Technology:Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 2Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 3Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 4Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 5Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 6Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2
(Date:5/24/2015)... (PRWEB) May 24, 2015 EnviroLeather™ ... launches “InkGard™ Plus” – a classic, rugged leather ... polymer allowing difficult stains, including ink, to be ... different colors suitable for corporate, healthcare, hospitality and ... line with EnviroLeather’s goal of developing products that ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 ... System CEO - The students ... honored at the fourth annual A ... 15 at Geneva National in Lake ... ,     -Badger High School,         Jonathan Alfonso, ...
(Date:5/23/2015)... May 23, 2015 With the implementation ... are finding it increasingly difficult to provide their employees ... to provide adequate insurance for employees stand to face ... such an integral part of a business’s success or ... for businesses, Online USA Doctors has created a varying ...
(Date:5/23/2015)... Janesville, WI (PRWEB) May 23, 2015 ... Mercy Acceleration at the Sports Medicine and Rehabilitation Center, ... running clinic program, Mondays, June 1-July 20, 5:30-6:30 pm. ... MS, USAT coach, and Laurie Finke, RN, BSN, who ... flexibility exercises, education on nutrition, running mechanics and show ...
(Date:5/22/2015)... Francisco, CA (PRWEB) May 22, 2015 ... hosting two exciting events in June. They will hold ... Professional Doctorate and a two-day class on Classical Chinese ... p.m. June 3, Dr. Steve Given, the Dean of ... will discuss the new First Professional Doctorate program. ACTCM ...
Breaking Medicine News(10 mins):Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:ACTCM Announces Upcoming June Events 2
... TORONTO, Feb. 12 /PRNewswire-FirstCall/ - Predictive medicine company,PreMD Inc. ... the company,s,business direction in light of the recent decision ... to the FDA, PreMD today filed a request ... accordance with the following Code of Federal Regulations 21,CFR ...
... Asoyia-MO is the first and only soybean oil to provide ... fats per serving, and light, clean taste., IOWA CITY, ... a new product that not only meets the increasing,consumer demand ... of stability and neutral taste so important to food processors., ...
... individuals or families may have underlying speech deficits ... a personal or family history of learning disabilities may ... dementia that causes them to lose language abilities as ... The condition, known as primary progressive aphasia, causes language ...
... Comprehensive Account of Global Trends, Progress and ... with Response Planning, ANNAPOLIS, Md., Feb. 12 ... global intelligence and business resiliency services,today announced the ... and,Pandemic Planning. Created by iJET,s health intelligence team, ...
... and American Heart Association Join Forces to,Educate, ... Health, CHICAGO, Feb. 12 A recent ... Heart,Association found that, among African-Americans, two out of ... and two out of,five (40 percent) expressed concern ...
... Hutchinson - Named President and CEO of Prematics(TM) - ... Advancing Physician Adoption of Electronic Prescribing, BETHESDA, ... named Kevin Hutchinson, one of the nation,s most respected ... chief,executive officer of SureScripts, to lead the company,s next ...
Cached Medicine News:Health News:PreMD Initiates FDA Review Process and Provides Corporate Update 2Health News:PreMD Initiates FDA Review Process and Provides Corporate Update 3Health News:Asoyia Announces New Mid Oleic Ultra Low Lin Soybean Oil 2Health News:Learning Disabilities May Presage Later Language Problems 2Health News:iJET Unveils 2007 Year-in-Review Report on Avian Influenza and Pandemic Planning 2Health News:iJET Unveils 2007 Year-in-Review Report on Avian Influenza and Pandemic Planning 3Health News:New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health 2Health News:New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health 3Health News:New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health 4Health News:Founding CEOS of SureScripts(R) and RxHub(R) Join Forces to Deliver Clinical Information Technology Services to Physician Practices 2Health News:Founding CEOS of SureScripts(R) and RxHub(R) Join Forces to Deliver Clinical Information Technology Services to Physician Practices 3
... Profile Ergonomic Design for Neurosurgery. ... offers rigid working channel scopes ... The rigid scope body facilitates ... the target. The steerable tip ...
... Ethisorb Dura Patch is a synthetic absorbable ... and. spinalis defects. Ethisorb Dura Patch is pliable, ... cut to the desired shape, care must be ... violet dyed, PDS foil covered side is oriented ...
... patch, Duragen is a matrix for ... handles and conforms similar to normal ... matrix for dural closure. Remarkable onlay ... defects. Fully resorbed following complete tissue ...
Elmed electrosurgical systems for major surgery....
Medicine Products: